Acadia Pharmaceuticals Inc.ACAD
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · acadia.com
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Key ratios
Operating cash flow growth
-14.7%TTM
2025
-30.4%2024
844.3%
EPS growth
66.4%TTM
2025
69.1%
FCF / Sales
9.8%2025
2024
16.4%2023
2.3%
Net margin
33.4%TTM
2025
36.5%2024
23.6%2023
-8.4%
ROA
3.6%TTM
2025
4.8%2024
5.4%2023
-6.9%
ROE
35.7%TTM
2025
39.9%2024
38.9%2023
-14.7%
Revenue growth
11.8%TTM
2025
11.9%2024
31.9%2023
40.5%
Track ACAD in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer